Precision Cancer Therapy in Rare Cancers

Last updated: March 23, 2025
Sponsor: Oslo University Hospital
Overall Status: Active - Recruiting

Phase

2

Condition

Neoplasms

Treatment

Imatinib

Trametinib

Dabrafenib

Clinical Study ID

NCT06119789
MATRIX-Rare
  • Ages 16-99
  • All Genders

Study Summary

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.

In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ECOG 0-2,

  • identified biomarker,

  • reasonable biochemistry

Exclusion

Exclusion Criteria:

  • ECOG 3-5

  • serious other diseases

Study Design

Total Participants: 96
Treatment Group(s): 3
Primary Treatment: Imatinib
Phase: 2
Study Start date:
March 20, 2025
Estimated Completion Date:
August 01, 2036

Study Description

All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.

Connect with a study center

  • Oslo University Hospital

    Oslo, 0310
    Norway

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.